Scientists from within the industry, academia, and two U.S. national laboratories are working to streamline the process for development of cancer drugs. They are creating an open and sharable platform that integrates high-performance computing, shared biological data from public and industry sources, and emerging biotechnologies to dramatically accelerate the discovery.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
